Open-Label, Randomized, Single Dose, Parallel Group, Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of Two Formulations of GSK5784283 Administered by Subcutaneous Injection

GlaxoSmithKline

Summary

The purpose of this study is to compare how two different formulations of the study medicine (GSK5784283) move through the body over time (pharmacokinetic \[PK\] study) in healthy adults. The aim of the study is to see how the body processes GSK5784283 and determine if the study medicine is safe, how well it is tolerated by the body and if the study medicines being tested work in the body in the same way.

Eligibility

Age range: 18–60 years
Sex: All
Healthy volunteers: Yes

Detailed criteria

Inclusion Criteria: * Participants who are healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and ECG. * Body weight greater than or equal (\>=) 50 kilogram (kg) (110 pounds \[lbs\]) and body mass index within the range 19 to 30 kilogram per meter square (kg/m\^2) (inclusive). * A female participant is eligible to participate if she is a participant of non-childbearing potential (PONCBP) as specified in the protocol. * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in…

Interventions

Drug
GSK5784283
GSK5784283 will be administered.

Location

GSK Investigational Site
Austin, Texas
GSKClinicalSupportHD@gsk.com 877-379-3718

Open-Label, Randomized, Single Dose, Parallel Group, Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of Two Formulations of GSK5784283 Administered by Subcutaneous Injection

Summary

Eligibility

Interventions

Location

Compensation

Run this study?

Details

Conditions